X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
Type of Medium
Language
Region
Library
Years
Person/Organisation
Subjects(RVK)
Keywords
Access
  • 1
    Book
    Book
    Patent strategy in pharmaceutical industry : are additional patents valuable? (2014)
    Baden-Baden : Nomos
    Details
    UID:
    b3kat_BV041756017
    Format: 84 S. , graph. Darst.
    Edition: 1. Aufl.
    ISBN: 9783848709915 , 3848709910
    Series Statement: MIPLC studies 20
    Note: Zugl.: Munich, Munich Intellectual Property Law Center, Masterarbeit, 2012
    Additional Edition: Erscheint auch als Online-Ausgabe ISBN 978-3-8452-5128-8
    Language: English
    Subjects: Law
    RVK:
    PJ 2960
    RVK:
    PJ 2880
    Keywords: Pharmazeutische Industrie ; Patentschutz ; Hochschulschrift
    URL: Volltext  (kostenfrei)
    URL: Inhaltsverzeichnis
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Book
    Fulltext
    EUV Frankfurt get availability status
    BTU Cottbus get availability status
  • 2
    Online Resource
    Online Resource
    Patent strategy in pharmaceutical industry : are additional patents valuable? (2014)
    Nomos Verlagsgesellschaft mbH & Co. KG | Baden-Baden, [Germany] :Nomos,
    Details
    UID:
    almahu_9949711193702882
    Format: 1 online resource (85 p.)
    Edition: 1. Auflage.
    ISBN: 3-8452-5128-X
    Series Statement: Munich Intellectual Property Law Center Studies ; Volume 20
    Content: This book investigates lifecycle management strategies used by pharmaceutical companies attempting to maximize the value of their product portfolio. Such strategies are sometimes referred to by generic drug companies as “evergreening”. The analysis focuses on two of these strategies, namely product improvements and product line extensions. In particular, an evaluation of the patents that follow the basic one and that accompany the development of a drug from research to market is attempted. Two “blockbuster” drugs, Taxotere and Xalatan, were randomly chosen to carry out such analysis. The patent portfolio of the originator companies is outlined and some important patents for each area of research (e.g. formulations, combinations, delivery devices) are shortly described. Patent filing trends for the two drugs, both in regards of the originator and in regards of other competing companies (amongst these also the generics) are schematically shown.
    Note: Description based upon print version of record. , Acronyms and Abbreviations; I. Introduction; II. Background; A. Pharmaceutical Industry - The Development of a New Drug.; B. New Drug Approval Regulations; C. Generic Drugs Approval.; III. Case Studies-Facts; A. Taxotere; 1. General; 2. Patent Portfolio; a) Process; b) Formulation; c) Combination Therapy; d) New Uses; e) Derivatives; 3. Use of Procedural Provisions: Supplementary Protection Certificates (SPCs)/Patent Term Extension; 4. Conclusion; B. Xalatan; 1. General; 2. Patent Portfolio; a) Process; b) Formulation; c) Combination Therapy; d) New Uses; e) Delivery Devices , f) Packaged Product3. Use of Procedural Provisions; a) Divisional of Basic Patent; b) Supplementary Protection; 4. Conclusion; IV. Discussion; A. Lifecycle Management: Criticism and Supports; B. Further Filing Strategy: Commercial Value; 1. Innovation Tracks; a) Formulations; b) Combinations; c) Process; d) New Uses; e) Delivery Devices; 2. Xalatan SPC Request: a Case for Competition Law?; C. Patent Strategy and Innovation; D. Summary: Taxotere v Xalatan; E. Conclusion and Suggestions; V. Final Remarks; List of works cited; Periodical Materials in English; Periodical Material in German , Non Periodical MaterialTable of books; Table of Cases; European Union; EPO Board of Appeal; France; Germany; Italy; United Kingdom; United States; Statutes; Speeches and Reports; Press release; Others , English
    Additional Edition: ISBN 3-8487-0991-0
    Language: English
    Keywords: Electronic books ; Hochschulschrift
    URL: Volltext  (kostenfrei)
    URL: kostenfrei
    URL: Volltext  (kostenfrei)
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    Fulltext
    Fulltext
    Stabi Berlin
    HU Berlin
  • 3
    Online Resource
    Online Resource
    Patent strategy in pharmaceutical industry : are additional patents valuable? (2014)
    Baden-Baden : Nomos Verlagsgesellschaft
    Details
    UID:
    gbv_1066614555
    Format: 1 Online-Ressource (85 pages)
    Edition: 1. Aufl
    ISBN: 9783845251288 , 384525128X , 384525128X , 9783845251288
    Series Statement: MIPLC studies v. 20
    Content: Acronyms and Abbreviations; I. Introduction; II. Background; A. Pharmaceutical Industry -- The Development of a New Drug.; B. New Drug Approval Regulations; C. Generic Drugs Approval.; III. Case Studies-Facts; A. Taxotere; 1. General; 2. Patent Portfolio; a) Process; b) Formulation; c) Combination Therapy; d) New Uses; e) Derivatives; 3. Use of Procedural Provisions: Supplementary Protection Certificates (SPCs)/Patent Term Extension; 4. Conclusion; B. Xalatan; 1. General; 2. Patent Portfolio; a) Process; b) Formulation; c) Combination Therapy; d) New Uses; e) Delivery Devices
    Content: F) Packaged Product3. Use of Procedural Provisions; a) Divisional of Basic Patent; b) Supplementary Protection; 4. Conclusion; IV. Discussion; A. Lifecycle Management: Criticism and Supports; B. Further Filing Strategy: Commercial Value; 1. Innovation Tracks; a) Formulations; b) Combinations; c) Process; d) New Uses; e) Delivery Devices; 2. Xalatan SPC Request: a Case for Competition Law?; C. Patent Strategy and Innovation; D. Summary: Taxotere v Xalatan; E. Conclusion and Suggestions; V. Final Remarks; List of works cited; Periodical Materials in English; Periodical Material in German
    Content: F) Packaged Product3. Use of Procedural Provisions; a) Divisional of Basic Patent; b) Supplementary Protection; 4. Conclusion; IV. Discussion; A. Lifecycle Management: Criticism and Supports; B. Further Filing Strategy: Commercial Value; 1. Innovation Tracks; a) Formulations; b) Combinations; c) Process; d) New Uses; e) Delivery Devices; 2. Xalatan SPC Request: a Case for Competition Law?; C. Patent Strategy and Innovation; D. Summary: Taxotere v Xalatan; E. Conclusion and Suggestions; V. Final Remarks; List of works cited; Periodical Materials in English; Periodical Material in German
    Content: Dieses Buch untersucht die Lifecycle-Management-Strategien, die von Pharma-Unternehmen eingesetzt werden, um den Wert ihres Produktportfolios zu maximieren. Solche Strategien werden manchmal von Generika-Unternehmen als "evergreening" bezeichnet. Die Analyse erfolgt anhand zwei zufällig ausgewählter "Blockbuster"--Medikamente, Taxotere und Xalatan und konzentriert sich auf zwei dieser Strategien, nämlich die Produktverbesserung und die Produktlinienerweiterung. Reihe Munich Intellectual Property Law Center - MIPLC - Band 20
    Note: Includes bibliographical references
    Additional Edition: ISBN 9783848709915
    Additional Edition: ISBN 9783848709915
    Additional Edition: Erscheint auch als Druck-Ausgabe Donghi, Monica Patent strategy in pharmaceutical industry: are additional patents valuable? Baden-Baden : Nomos, 2014 ISBN 3848709910
    Additional Edition: ISBN 9783848709915
    Additional Edition: Print version Donghi, Monica Patent Strategy in Pharmaceutical Industry: Are additional patents valuable? Baden-Baden : Nomos Verlagsgesellschaft, ©2014 ISBN 9783848709915
    Language: English
    Subjects: Law
    RVK:
    PJ 2960
    Keywords: Electronic books
    URL: Volltext  (kostenfrei)
    URL: kostenfrei
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    Fulltext
    Stabi Berlin
  • 4
    Online Resource
    Online Resource
    Patent strategy in pharmaceutical industry : are additional patents valuable? (2014)
    Nomos Verlagsgesellschaft mbH & Co. KG | Baden-Baden, [Germany] :Nomos,
    Details
    UID:
    edoccha_9958982584902883
    Format: 1 online resource (85 p.)
    Edition: 1. Auflage.
    ISBN: 3-8452-5128-X
    Series Statement: Munich Intellectual Property Law Center Studies ; Volume 20
    Content: This book investigates lifecycle management strategies used by pharmaceutical companies attempting to maximize the value of their product portfolio. Such strategies are sometimes referred to by generic drug companies as “evergreening”. The analysis focuses on two of these strategies, namely product improvements and product line extensions. In particular, an evaluation of the patents that follow the basic one and that accompany the development of a drug from research to market is attempted. Two “blockbuster” drugs, Taxotere and Xalatan, were randomly chosen to carry out such analysis. The patent portfolio of the originator companies is outlined and some important patents for each area of research (e.g. formulations, combinations, delivery devices) are shortly described. Patent filing trends for the two drugs, both in regards of the originator and in regards of other competing companies (amongst these also the generics) are schematically shown.
    Note: Description based upon print version of record. , Acronyms and Abbreviations; I. Introduction; II. Background; A. Pharmaceutical Industry - The Development of a New Drug.; B. New Drug Approval Regulations; C. Generic Drugs Approval.; III. Case Studies-Facts; A. Taxotere; 1. General; 2. Patent Portfolio; a) Process; b) Formulation; c) Combination Therapy; d) New Uses; e) Derivatives; 3. Use of Procedural Provisions: Supplementary Protection Certificates (SPCs)/Patent Term Extension; 4. Conclusion; B. Xalatan; 1. General; 2. Patent Portfolio; a) Process; b) Formulation; c) Combination Therapy; d) New Uses; e) Delivery Devices , f) Packaged Product3. Use of Procedural Provisions; a) Divisional of Basic Patent; b) Supplementary Protection; 4. Conclusion; IV. Discussion; A. Lifecycle Management: Criticism and Supports; B. Further Filing Strategy: Commercial Value; 1. Innovation Tracks; a) Formulations; b) Combinations; c) Process; d) New Uses; e) Delivery Devices; 2. Xalatan SPC Request: a Case for Competition Law?; C. Patent Strategy and Innovation; D. Summary: Taxotere v Xalatan; E. Conclusion and Suggestions; V. Final Remarks; List of works cited; Periodical Materials in English; Periodical Material in German , Non Periodical MaterialTable of books; Table of Cases; European Union; EPO Board of Appeal; France; Germany; Italy; United Kingdom; United States; Statutes; Speeches and Reports; Press release; Others , English
    Additional Edition: ISBN 3-8487-0991-0
    Language: English
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    Charité
  • 5
    Online Resource
    Online Resource
    Patent Strategy in Pharmaceutical Industry: Are additional patents valuable? (2014)
    Baden-Baden : Nomos Verlagsgesellschaft mbH & Co. KG
    Details
    UID:
    almahu_9947932683802882
    Format: 1 online resource
    Edition: 1. Auflage 2014
    ISBN: 9783845251288 (Online) , 9783848709915 (Print)
    Content: Dieses Buch untersucht die Lifecycle-Management-Strategien, die von Pharma-Unternehmen eingesetzt werden, um den Wert ihres Produktportfolios zu maximieren. Solche Strategien werden manchmal von Generika-Unternehmen als „evergreening“ bezeichnet. Die Analyse erfolgt anhand zwei zufällig ausgewählter „Blockbuster“-Medikamente, Taxotere und Xalatan und konzentriert sich auf zwei dieser Strategien, nämlich die Produktverbesserung und die Produktlinienerweiterung.
    Language: English
    URL: https://doi.org/10.5771/9783845251288
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    HU Berlin
  • 6
    Online Resource
    Online Resource
    Patent strategy in pharmaceutical industry : are additional patents valuable? (2014)
    Nomos Verlagsgesellschaft mbH & Co. KG | Baden-Baden, [Germany] :Nomos,
    Details
    UID:
    edocfu_9958982584902883
    Format: 1 online resource (85 p.)
    Edition: 1. Auflage.
    ISBN: 3-8452-5128-X
    Series Statement: Munich Intellectual Property Law Center Studies ; Volume 20
    Content: This book investigates lifecycle management strategies used by pharmaceutical companies attempting to maximize the value of their product portfolio. Such strategies are sometimes referred to by generic drug companies as “evergreening”. The analysis focuses on two of these strategies, namely product improvements and product line extensions. In particular, an evaluation of the patents that follow the basic one and that accompany the development of a drug from research to market is attempted. Two “blockbuster” drugs, Taxotere and Xalatan, were randomly chosen to carry out such analysis. The patent portfolio of the originator companies is outlined and some important patents for each area of research (e.g. formulations, combinations, delivery devices) are shortly described. Patent filing trends for the two drugs, both in regards of the originator and in regards of other competing companies (amongst these also the generics) are schematically shown.
    Note: Description based upon print version of record. , Acronyms and Abbreviations; I. Introduction; II. Background; A. Pharmaceutical Industry - The Development of a New Drug.; B. New Drug Approval Regulations; C. Generic Drugs Approval.; III. Case Studies-Facts; A. Taxotere; 1. General; 2. Patent Portfolio; a) Process; b) Formulation; c) Combination Therapy; d) New Uses; e) Derivatives; 3. Use of Procedural Provisions: Supplementary Protection Certificates (SPCs)/Patent Term Extension; 4. Conclusion; B. Xalatan; 1. General; 2. Patent Portfolio; a) Process; b) Formulation; c) Combination Therapy; d) New Uses; e) Delivery Devices , f) Packaged Product3. Use of Procedural Provisions; a) Divisional of Basic Patent; b) Supplementary Protection; 4. Conclusion; IV. Discussion; A. Lifecycle Management: Criticism and Supports; B. Further Filing Strategy: Commercial Value; 1. Innovation Tracks; a) Formulations; b) Combinations; c) Process; d) New Uses; e) Delivery Devices; 2. Xalatan SPC Request: a Case for Competition Law?; C. Patent Strategy and Innovation; D. Summary: Taxotere v Xalatan; E. Conclusion and Suggestions; V. Final Remarks; List of works cited; Periodical Materials in English; Periodical Material in German , Non Periodical MaterialTable of books; Table of Cases; European Union; EPO Board of Appeal; France; Germany; Italy; United Kingdom; United States; Statutes; Speeches and Reports; Press release; Others , English
    Additional Edition: ISBN 3-8487-0991-0
    Language: English
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    FU Berlin
Nothing or not found what you are looking for? Please check your search query or use the Interlibrary Loan Search.
Did you mean 9783848704965?
Did you mean 9783848700905?
Did you mean 9783848705115?
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages